A deal with Sandoz to lead the global launch of Pear's two lead products puts marketing muscle behind the nascent class of 'prescription digital therapeutics.'
The most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.
Teva to cut thousands of U.S. jobs; Regeneron drops Eylea combo drug development; insurers, drugstores, and hospitals increasingly teaming up
GSK hires Google biotech exec to lead R&D; Merck gets FDA-approval for CMV therapy; ex-Lilly exec reportedly top HHS secretary pick
Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.
Sanofi ties price increases to growth rate; Regeneron to target 7,000 docs on new eczema drug Dupixent; NIH and biotech execs meet White House officials
Pharma among top sponsors of Trump inauguration parties; AstraZeneca exec to replace GSK president of global pharmaceuticals; EpiPen rival to relaunch
Here's a look at 100 experimental therapies in late-stage clinical trials.
Repatha and Praluent launches described by analyst as waste of money; AstraZeneca halts trial for cancer drug; health exchange choices dwindle
The current reimbursement climate is more likely to impact how drugmakers order their global product launches than the U.K.'s vote to exit the E.U.
One oft-cited challenge to Entresto's adoption has been prior authorization requirements.
After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.
Valeant terminates Addyi's sales force; the Treasury Department issues new tax-inversion rules; MannKind buys back its marketing rights to Afrezza
The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.
From clinical trials to customer planning, digital can speed the biopharma product launch at each step, said Nancy Phelan, BMS head of commercial operations, at last week's MM&M Leadership Exchange.
Sandoz plans to take a branded approach as it launches the first FDA-approved biosimilar product.
Shire offers to buy Baxalta for $30 billion; CVS reports strong sales in specialty pharmacy; Reuters reports that new drug launches hit 17-year high in 2014
Experimental Alzheimer's disease drugs produce mixed results; court rules in favor of Novartis in Zarxio case; Horizon Pharma increases its bid for Depomed
The modern healthcare landscape is complicated, and the terrain is even more gnarled for life sciences companies trying to bring new products to market.
The Lions Health award winners will be announced later Friday at an event in Cannes, France.
Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.
Drugmakers engage early with insurers; patients push for implant to be pulled from the market; about one-third of new drugs qualify for special approval pathways
Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales
Americans spent 13.1% more on prescription medications in 2014 than they did in 2013, but recent launches indicate competition in the specialty drug space is going to heat up.
After weeks of speculation as to whether MannKind would find a marketing partner for its inhalable insulin, the drugmaker said today that Sanofi would acquire global licensing rights to the drug for $925 million.
The painkiller's marketer will look to partner with another manufacturer to better target primary care physicians, and will also reexamine its sales territories.
Arena's recent quarter shows weight-loss drug Belviq is on the rise. It follows a DTC push and the recent addition of reps by co-marketer Eisai.
Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?
Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.
Kynamro's slow start, coupled with competition, has prompted Sanofi to add sales reps.